Geneticure is a Mayo Clinic backed company that has created a cheek-swab test that can predict individual treatment response for high blood pressure medications. The current standard of care is trial-and-error with medications. The patented technology leans on the genetics of integrative physiology and in three clinical trials on nearly 1k subjects has demonstrated 36% greater blood pressure reduction than standard of care at 47% less cost. The company also has a patent-pending panel in development to better triage and treat COVID-19 based on genetics. This technology is being studied with partners at UnitedHealth Group. Two additional collaborations are in development with Medtronic (genetic companion diagnostic for device) and Mayo Clinic (Confidential)